To assess the relationship between mutations in Plasmodium falciparum dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) and clinical pyrimethamine-sulfadoxine resistance, polymerase chain reaction surveys and analyses for new mutations were conducted in four countries with increasing levels of pyrimethamine-sulfadoxine resistance: Mali, Kenya, Malawi, and Bolivia. Prevalence of mutations at DHFR codon 108 and a new mutation at DHPS 540 correlated with increased pyrimethamine-sulfadoxine resistance (P õ .05). Mutations at DHFR 51, DHFR 59, and DHPS 437 correlated with resistance without achieving statistical significance. Mutations at DHFR 164 and DHPS 581 were common in Bolivia, where pyrimethamine-sulfadoxine resistance is widespread, but absent in African sites. Two new DHFR mutations, a point mutation at codon 50 and an insert at codon 30, were found only in Bolivia. DHFR and DHPS mutations occur in a progressive, stepwise fashion. Identification of specific sets of mutations causing in vivo drug failure may lead to the development of molecular surveillance methods for pyrimethamine-sulfadoxine resistance.
Pyrimethamine-sulfadoxine served as the first line of defense the only currently available, affordable alternative for the treatagainst chloroquine-resistant Plasmodium falciparum malaria ment of uncomplicated malaria in areas of Africa with extenin South America and Southeast Asia, where clinical resistance sive chloroquine resistance. Deterring the spread of pyrimethto pyrimethamine-sulfadoxine arose rapidly after widespread amine-sulfadoxine -resistant malaria is an urgent public health use began. This combination of antifolate drugs now represents objective, particularly in Africa, and will require the ability to map pyrimethamine-sulfadoxine -resistant malaria quickly and accurately. Neither in vivo surveys nor in vitro chemosensitivity testing methods for measuring drug-resistant malaria are lance [1] . gives a synergistic action against P. falciparum [2] . In vitro methamine-sulfadoxine resistance, Mali, Kenya, Malawi, and Bolivia were ranked in that order as sites with lowest to highest levels of in vivo pyrimethamine-sulfadoxine resistance, each at a further
Materials and Methods
point along a time line of pyrimethamine-sulfadoxine use. Sample collection and DNA extraction. Fingerstick blood from Study sites. In Mali, chloroquine remains effective (unpublished data), and national malaria control policy reserves pyrimethpersons presenting to clinics with uncomplicated, microscopically confirmed P. falciparum malaria was collected onto filter paper amine-sulfadoxine for treatment of cases of chloroquine failure. Of cases of malaria at the study site (n Å 218), 99% exhibited a strips, and DNA was extracted by use of a chelating resin (Chelex-100; Bio-Rad, Richmond, CA) as described [1] . sensitive response to pyrimethamine-sulfadoxine at the time of this study [23] . Resistance definitions (RI, RII, and RIII) are based on Mutation-specific PCR. Nested mutation-specific PCR was done as previously described for analysis of the DHFR 108 and those of the World Health Organization: RI is the disappearance of parasitemia after pyrimethamine-sulfadoxine therapy followed 164 mutation sites [1, 20] . Amplified DHFR domain from the first round of PCR, which used the oligonucleotide primer pair AMP1 by recurrent parasitemia; RII resistance is a §75% diminution of parasitemia followed by a subsequent rise in parasitemia; and RIII and AMP2 as described [1] , was used in mutation-specific secondround PCR to assess the DHFR mutation sites 51 and 59. For resistance is õ75% or no diminution of parasitemia following therapy. Therapeutic failure refers to RII or RIII resistance and codon 51, mutation-specific sense primers FR51w (5-TTACCA-TGGAAATGTAA-3), which specifically amplifies sequence conpersistence or recurrence of symptoms. Samples were collected in 1995 at two clinics on the outskirts of Bamako, the capital city taining the wild type AAT (Asn) codon, and FR51m (5-TTACCA-TGGAAATGTAT-3) [22] , which is specific for the mutant codon of Mali.
ATT (Ile), were paired with the common antisense primer SP2 [20] , for a final product of 514 bp. Taq DNA polymerase (Life Technologies GIBCO BRL, Gaithersburg, MD) was used with the manufacturer's buffer containing 2.5 mM MgCl 2 , primers were used at 1 mM, and other reaction conditions were as described [1] with these cycling parameters: initial denaturation at 95ЊC for 3 min, followed by 15 cycles of denaturation at 92ЊC for 30 s, annealing at 52ЊC for 45 s, and extension at 72ЊC for 45 s, and a Figure 1 . A, Restriction digestion method for detecting dihydrofofinal extension at 72ЊC for 3 min. For analysis of the DHFR 59 late reductase (DHFR) Arg-50 mutation. Lane 1 Å 720-bp polymerase codon, the antisense primers FR59w (5-ATGTTGTAACTGchain reaction (PCR) -amplified DHFR domain from sample con-CACA-3), specific for the TGT (Cys) wild type and FR59m ( Medicine. analysis of codon 581 and the Thr-613 mutation were as above Molecular modeling. A computer-generated model of the enexcept for an annealing temperature of 52ЊC. Products were anaergy-minimized tertiary structure (TS) of DHFR was created using lyzed on a 1.5% agarose gel containing ethidium bromide.
InsightII (Biosym Technologies, San Diego). The primary seMutation-specific restriction analysis. Presence of the DHPS quence of the P. falciparum DHFR-TS was aligned with the exmutations at codon 436 and 437 were evaluated by digest of the tracted sequence from the Leishmania major DHFR-TS [26], and primers 185/218 [21]-amplified DHPS domain with MspA1I, homology modeling and energy minimization were performed on which exclusively cleaves the Ala-436 mutant sequence, and AvaII, an Iris indigo XZ4000 computer (Silicon Graphics, Mountain which exclusively cleaves the mutant Gly-437 sequence. Presence View, CA). of the new DHFR mutation at codon 50 was determined by restricData analysis. Prevalence rates for each mutation represent tion digestion of SP1/SP2 [20]-amplified DHFR domain with TaiI, the number of infections at a site containing the mutant genotype, which cleaves the mutated sequence but not the wild type (figure divided by the total number of infections from that site analyzed 1). Detection of the DHFR Bolivia repeat was done by size deterfor the presence of that mutation. Mutations were determined to mination of the amplified PCR product corresponding to the DHFR be present or absent on the basis of the presence or absence of domain 5 to codon 59 (figure 1). The new DHPS Glu-540 mutation the expected bands on ethidium-stained agarose gel analysis of was detected by digestion with FokI, which cleaves the mutated diagnostic PCR product and restriction digestions. Gels were resequence (figure 1). All digests were done in 20-mL reactions corded by video photography. containing 5 mL of unpurified PCR product, buffered and incubated Statistical analysis. Spearman correlation coefficients between according to supplier's specifications (New England BioLabs, Bevrank of sites by pyrimethamine-sulfadoxine resistance and rank erly, MA), and analyzed on 1.5%-2.0% agarose gels containing of prevalence for each mutation were determined with SPSS for ethidium bromide. and 3. DHFR Asn-108, which must be present before additional sequenced to determine if additional new mutations had appeared in this setting. One sample was determined to harbor a mutations conferring higher-level pyrimethamine resistance can occur [27] , is present at all sites and correlates with innew single base alteration causing a CysjArg change at DHFR codon 50, and 2 samples contained an in-frame 15 bp creased pyrimethamine-sulfadoxine use and resistance (r Å 1.00, P õ .05). DHFR Ile-51 (r Å 0.95, P Å .05) and repeat inserted between aa 30 and 31, termed the Bolivia repeat (figure 4). A computer-generated model of the tertiary protein (r Å 0.40, P Å .60) show a similar trend, with the exceptions that Ile-51 is universal in both Malawi and Bolivia and Argstructure of P. falciparum DHFR suggests that the Bolivia repeat lies adjacent to the active site of DHFR (figure 5). 59 is less prevalent in Bolivia than in the African sites. DHFR Leu-164 (r Å 0.78, P Å .23), which has not previously been Methods were devised to identify both new DHFR mutations and used to screen additional samples from all four study sites reported outside of Southeast Asia, and DHPS Gly-581 (r Å 0.78, P Å .23), were observed at high frequencies in Bolivia for their presence. The Arg-50 mutation was found in 52.5% (n Å 40) of Bolivian samples tested, and its presence was but were not found in any of the African countries surveyed. DHPS Gly-437 (r Å 0.80, P Å .20), while more frequent in confirmed by direct sequencing of PCR-amplified DHFR from 3 of these samples. The Bolivia repeat was detected in 43.8% Mali than in Kenya, otherwise tended to increase with increased in vivo resistance, but the paired DHPS mutations at positions (n Å 48) of Bolivian samples and confirmed by direct sequencing of PCR product in 1 of these. Both new DHFR mutations 436 and 613 (r Å 00.78, P Å .23) were rare in Africa and absent in Bolivia. The Ala-436 DHPS mutation (r Å 01.00, were absent in the three African countries surveyed (figure 6).
No additional new DHFR mutations were found among a total P õ .05) was inversely associated with drug use and in vivo resistance. The DHFR Thr-108 mutation associated with cycloof 8 Bolivian samples and 6 Malawian samples sequenced. Clonal analysis revealed that the two new DHFR mutations guanil resistance was not detected in samples from any site.
New DHFR mutations. On the basis of the finding of a do not occur together in the same gene, although they can occur together in a single, polyclonal field sample. In PCR high prevalence of previously identified DHFR and DHPS mutations in Bolivia, PCR-amplified DHFR from 3 Bolivian samanalysis of cloned field-derived DHFR, both new mutations were found to occur only in combination with the previously ples containing multiple DHFR mutations (as detected by diagnostic nested PCR) was cloned, and a total of 7 clones were identified Ile-51 mutation but not with the Arg-59 mutation. / 9d3b$$de28 10-29-97 18:10:13 jinfal UC: J Infect 59. The correlation of rates of DHFR Asn-108, Ile-51, and Arg-59 mutations with pyrimethamine-sulfadoxine use and in vivo resistance at the sites in Africa suggests that pyrimethamine-sulfadoxine treatment is selective for these mutations, but their high prevalence in these settings, where therapeutic view that these three mutations are insufficient for high-level in vivo pyrimethamine-sulfadoxine resistance. The DHFR Leu-164 mutation was found only in Bolivia, where high-level in The Bolivia repeat was found only in combination with the vivo resistance is common. Leu-164 has previously been reLeu-164 mutation in 25 clones from 5 samples (5 clones anaported only in P. falciparum strains from Southeast Asia [6, lyzed per sample), while Arg-50 occurred with the wild type 11], another area of widespread pyrimethamine-sulfadoxine reIle-164 in 23 of 24 clones analyzed. One of 24 clones was sistance, suggesting that this mutation appears late in the course confirmed by sequencing to contain the Arg-50 mutation with of development of pyrimethamine-sulfadoxine resistance and the mutant Leu-164.
is likely to play a role in therapeutic failure. New DHPS mutation. DHPS from 4 Bolivian samples of Our analyses are consistent with earlier studies [6, 11, 12 , P. falciparum DNA was amplified by PCR and directly se-27] confirming that the DHFR mutations occur in a stepwise quenced, and a new point mutation causing a LysjGlu change fashion. Initial mutations conferring low-level pyrimethamine at codon 540 was detected in all 4 of these. Restriction digestion resistance must be present for high-level resistance mutations methods were used to screen samples for the presence of this to appear. Some mutations appear to be mutually exclusive, an new mutation and to determine its prevalence at all four study observation that may be explained by deleterious effects of sites. The presence of this mutation (and absence of other certain combinations of mutations on enzyme function. new mutations) was confirmed by direct sequencing of PCRPrevalence rates of the DHPS mutations are less clearly amplified DHPS domains from 3 Malawian samples detercorrelated with pyrimethamine-sulfadoxine resistance. The mined by restriction digestion methods to contain Glu-540. The high prevalence of Gly-581 in Bolivia and the correlation beGlu-540 DHPS mutation was strongly correlated with in vivo tween prevalence of Gly-437 and Glu-540 and in vivo resisresistance (r Å 1.00, P õ .05; figure 6 ). This mutation has tance are consistent with a role in therapeutic pyrimethaminebeen independently discovered in P. falciparum isolates from sulfadoxine failure for these mutations. However, despite their Thailand [28] .
association with in vitro sulfadoxine resistance, the mutations PCR analysis of individual clones showed that both the Glyat positions 436 and 613 do not correlate with in vivo pyrimeth-581 and the new Glu-540 mutations only occur in the presence amine-sulfadoxine resistance. This disparity may be because of the Gly-437 and that Ala-436 and Gly-437 are rarely present the sub-physiologic folate and PABA conditions used in sulfaon the same molecule: Only 3 of 91 DHPS clones derived doxine in vitro susceptibility studies do not reflect in vivo from African samples that harbored either Ala-436 or Gly-437 contained both mutations. Ala-436 was never observed to occur with the Glu-540 and Gly-581 mutations.
Discussion
Despite an increasingly precise understanding of the molecular basis of in vitro resistance of P. falciparum to the antifolate drugs, the determinants of therapeutic failure of the combination of pyrimethamine and sulfadoxine remain unknown. The studies reported here identify those mutations most likely to be important in clinical antifolate resistance, demonstrate the feasibility of using simple molecular methods to conduct surveillance for drug resistance mutations on a large scale, and identify new mutations in both DHFR and DHPS that may contribute to in vivo pyrimethamine-sulfadoxine resistance.
All of the DHFR mutations grow more prevalent in areas with increased pyrimethamine-sulfadoxine use and resistance, with the exception that Arg-59 was less prevalent in Bolivia, conditions [14] . An alternative explanation is offered by the RIII resistance may require the additional presence of DHFR-164, the Bolivia repeat and/or DHPS 581. Because of the polystepwise fashion in which these mutations occur: The Ala-436 mutation is most common in settings of less pyrimethamineclonal nature of natural P. falciparum infections [29] and the impact of other factors, such as immunity [30] and host folate sulfadoxine use and resistance but is rarely paired with the Gly-437 mutation and occurs neither with Glu-540 (which correlates levels [31], on pyrimethamine-sulfadoxine treatment outcome, there will likely be overlap among the categories of resistance strongly with in vivo pyrimethamine-sulfadoxine resistance) nor with Gly-581 (which is found only in an area of widespread, seen with each combination of mutations.
Proof that specific DHFR and DHPS mutations cause in vivo high-level pyrimethamine-sulfadoxine resistance). Thus, while Ala-436 may provide an advantage under low levels of selecpyrimethamine-sulfadoxine resistance will require prospective studies of the relationship between parasite genotype and clinitive pressure from sulfa drugs, this mutation appears to preclude the progressive addition of the mutations most associated with cal outcome in individual infections treated with pyrimethamine-sulfadoxine. If a limited set of DHFR and DHPS mutapyrimethamine-sulfadoxine resistance and would lose its selective advantage under conditions of more intense drug pressure.
tions can be identified as predictive of in vivo pyrimethaminesulfadoxine resistance, it will be possible to conduct broad It is also possible that DHPS mutations are not the major determinants of clinical pyrimethamine-sulfadoxine resistance, surveillance for pyrimethamine-sulfadoxine resistance. This capability will be particularly important in sub-Saharan Africa, either because synergy depends primarily on pyrimethamine response [19] or because other mechanisms contribute to sulfawhere the question of whether and when to use pyrimethaminesulfadoxine is becoming increasingly urgent. However, molecdoxine resistance [16] .
Several lines of reasoning support the hypothesis that the ular methods for monitoring pyrimethamine-sulfadoxine resistance will also be useful in settings such as Bolivia, to deternew DHFR Bolivia repeat and Arg-50 mutations are involved in resistance. First, these mutations are found only in an area mine whether, once established, high levels of resistance will subsequently fall to levels allowing the reintroduction of pyriof the world with very high rates of in vivo pyrimethaminesulfadoxine resistance, where they are highly prevalent. Secmethamine-sulfadoxine. A number of antifolate compounds and combination drugs are under consideration as potential ond, all previously identified naturally occurring DHFR mutations examined confer resistance, and finally, the Arg-50 mutareplacements for pyrimethamine-sulfadoxine, and defining the relationship between DHFR and DHPS mutations and resistion is located at the active site pocket of DHFR, where drug binding occurs [3] , and molecular modeling suggests that the tance to these drugs will aid in selecting the most suitable candidates among them. Continued surveillance for and analyBolivia repeat mutation also lies adjacent to this site ( figure  5 ). The strong correlation between prevalence of the new DHPS sis of new mutations in target molecules will be key to the successful development and deployment of molecular assays Glu-540 mutation and in vivo pyrimethamine-sulfadoxine resistance suggests that it too contributes to resistance.
for drug-resistant malaria. We hypothesize that RI, RII, and RIII levels of in vivo pyrimethamine-sulfadoxine resistance are due to the progres-
